Publikationen in Zusammenarbeit mit Forschern von University of Verona (72)

2024

  1. Correction to: Is antiviral treatment at the acute phase of COVID-19 effective for decreasing the risk of long-COVID? A systematic review (Infection, (2024), 52, 1, (43-58), 10.1007/s15010-023-02154-0)

    Infection

  2. Current management of SARS-CoV-2 infection in solid organ transplant recipients: Experience derived from an ESGICH–ESOT survey

    Transplant Infectious Disease, Vol. 26, Núm. 2

  3. Does the Impact of COVID-19 on Patients With Systemic Sclerosis Change Over Time?

    Arthritis Care and Research, Vol. 76, Núm. 1, pp. 88-97

  4. Is antiviral treatment at the acute phase of COVID-19 effective for decreasing the risk of long-COVID? A systematic review

    Infection, Vol. 52, Núm. 1, pp. 43-58

2023

  1. Erratum : World Allergy Organization Anaphylaxis Guidance 2020 [Japanese Journal of Allergology Vol.70 (2021) No.9 p.1211-1234]

    Arerugi = [Allergy], Vol. 72, Núm. 3, pp. 314

  2. Sarcopenic obesity research perspectives outlined by the sarcopenic obesity global leadership initiative (SOGLI) – Proceedings from the SOGLI consortium meeting in rome November 2022

    Clinical Nutrition

2022

  1. International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis

    JAMA Dermatology, Vol. 158, Núm. 5, pp. 561-572

  2. Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food—A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 77, Núm. 6, pp. 1736-1750

2021

  1. Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study

    Journal of Allergy and Clinical Immunology, Vol. 147, Núm. 1, pp. 60-71

  2. Quantifying duration of proteinuria remission and association with clinical outcome in IgA nephropathy

    Journal of the American Society of Nephrology, Vol. 32, Núm. 2

  3. Safety and activity of the TGFβ receptor i kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3

  4. World Allergy Organization Anaphylaxis Guidance 2020

    Arerugi = [Allergy], Vol. 70, Núm. 9, pp. 1211-1234

2020

  1. A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease

    Scientific Reports, Vol. 10, Núm. 1

  2. Antifungal susceptibility testing in Candida, Aspergillus and Cryptococcus infections: are the MICs useful for clinicians?

    Clinical Microbiology and Infection, Vol. 26, Núm. 8, pp. 1024-1033

  3. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

    Leukemia, Vol. 34, Núm. 9, pp. 2354-2363

  4. Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis

    Frontiers in Pediatrics, Vol. 8

  5. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

    The Lancet Oncology, Vol. 21, Núm. 1, pp. 105-120

  6. World allergy organization anaphylaxis guidance 2020

    World Allergy Organization Journal, Vol. 13, Núm. 10

2019

  1. GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways

    Nature Communications, Vol. 10, Núm. 1

  2. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: A prospective cohort study

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 7, pp. 979-987